Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability and efficacy of intranasal
ALN-RSV01 versus placebo, administered once daily for 5 days to a healthy male volunteers
experimentally inoculated with RSV